DD DuPont

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Plastic Materials, Synth Resins & Nonvulcan ElastomersSEC EDGAR

DuPont (DD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • Cash and equivalents $1.955B Sep 30, 2025 vs $1.843B Dec 31, 2024; total debt $8.899B vs $7.171B, driven by Qnity Notes issuance
  • Operating cash flow $1.260B YTD Sep 2025 vs $1.517B YTD Sep 2024; financing cash inflow $1.155B vs outflow $1.665B due to debt issuance
+3 more insights

Risk Factors

  • New trade disputes risk from U.S. tariffs on Canada, Mexico, China impacting supply chains and R&D, triggered by recent U.S. government tariffs announcements
  • Most materially updated regulatory risk: SAMR antitrust investigation on Tyvek® business in China, suspended July 22, 2025; Tyvek® sales to China approx. $90 million in 2024
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.4B

Net Income

-$123M

Net Margin

-5.1%

ROE

-0.5%

Total Assets

$38.0B

Source: XBRL data from DuPont Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other DuPont Quarterly Reports

Get deeper insights on DuPont

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.